Magali Lacroix-Triki

Magali Lacroix-Triki

Auto-generated profile, based on publicly available information

Magali Lacroix-Triki

Institut Gustave Roussy, Villejuif, France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
FMFernanda Mosele
Fernanda Mosele
EDelise deluche
elise deluche
ALAmelie Lusque
Amelie Lusque
LBLoïc Le Bescond
Loïc Le Bescond
TFThomas Filleron
Thomas Filleron
FAFabrice André
Fabrice André
The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing (n = 72, cohort 1), HER2-low (n = 74, cohort 2) and HER2 non-expressing (n = 40, cohort 3) metastatic breast cancer. In the full analysis set population (n = 177), the confirmed objective response rate (primary endpoint) was 70.6% (95% confidence interval (CI) 58.3–81) in cohort 1, 37.5% (95% CI 26.4–49.7) in cohort 2 and 29.7% (95% CI 15.9–47) in cohort 3. The primary endpoint was met in cohorts 1 and 2. Secondary endpoints included safety. No new safety signals were observed. During treatment, HER2-expressing tumors (n = 4) presented strong T-DXd staining. Conversely, HER2 immunohistochemistry 0 samples (n = 3) presented no or very few T-DXd staining (Pearson correlation coefficient r = 0.75, P = 0.053). Among patients with HER2 immunohistochemistry 0 metastatic breast cancer, 5 of 14 (35.7%, 95% CI 12.8–64.9) with ERBB2 expression below the median presented a confirmed objective response as compared to 3 of 10 (30%, 95% CI 6.7–65.2) with ERBB2 expression above the median. Although HER2 expression is a determinant of T-DXd efficacy, our study suggests that additional mechanisms may also be involved. (ClinicalTrials.gov identifier NCT04132960.)

19 January 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JTJean Ogier du Terrail
Jean Ogier du Terrail
ALArmand Leopold
Armand Leopold
CJClément Joly
Clément Joly
CBConstance Béguier
Constance Béguier
MAMathieu Andreux
Mathieu Andreux
PHPierre Etienne HEUDEL
Pierre Etienne HEUDEL

16 April 2021 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
TGThomas Grinda
Thomas Grinda
NJNatacha Joyon
Natacha Joyon
ALAmélie Lusque
Amélie Lusque
SLSarah Lefèvre
Sarah Lefèvre
LALaurent Arnould
Laurent Arnould
MLMagali Lacroix-Triki
Magali Lacroix-Triki
Expression of hormone receptor (HR) for estrogens (ER) and progesterone (PR) and HER2 remains the cornerstone to define the therapeutic strategy for breast cancer patients. We aimed to compare phenotypic profiles between matched primary and metastatic breast cancer (MBC) in the ESME database, a National real-life multicenter cohort of MBC patients. Patients with results available on both primary tumour and metastatic disease within 6 months of MBC diagnosis and before any tumour progression were eligible for the main analysis. Among the 16,703 patients included in the database, 1677 (10.0%) had available biopsy results at MBC diagnosis and on matched primary tumour. The change rate of either HR or HER2 was 27.0%. Global HR status changed (from positive = either ER or PR positive, to negative = both negative; and reverse) in 14.2% of the cases (expression loss in 72.5% and gain in 27.5%). HER2 status changed in 7.8% (amplification loss in 45.2%). The discordance rate appeared similar across different biopsy sites. Metastasis to bone, HER2+ and RH+/HER2- subtypes and previous adjuvant endocrine therapy, but not relapse interval were associated with an HR discordance in multivariable analysis. Loss of HR status was significantly associated with a risk of death (HR adjusted = 1.51, p = 0.002) while gain of HR and HER2 discordance was not. In conclusion, discordance of HR and HER2 expression between primary and metastatic breast cancer cannot be neglected. In addition, HR loss is associated with worse survival. Sampling metastatic sites is essential for treatment adjustment.

11 January 2022 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
SLSherene Loi
Sherene Loi
RSRoberto Salgado
Roberto Salgado
SASylvia Adams
Sylvia Adams
GPGiancarlo Pruneri
Giancarlo Pruneri
PFPrudence A. Francis
Prudence A. Francis
SMStefan Michiels
Stefan Michiels
The importance of integrating biomarkers into the TNM staging has been emphasized in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging system. In a pooled analysis of 2148 TNBC-patients in the adjuvant setting, TILs are found to strongly up and downstage traditional pathological-staging in the Pathological and Clinical Prognostic Stage Groups from the AJJC 8th edition Cancer Staging System. This suggest that clinical and research studies on TNBC should take TILs into account in addition to stage, as for example patients with stage II TNBC and high TILs have a better outcome than patients with stage I and low TILs.

4 September 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
BPBarbara Pistilli
Barbara Pistilli
FMFernanda Mosele
Fernanda Mosele
NCNoemie Corcos
Noemie Corcos
LPLivia Pierotti
Livia Pierotti
YPYoann Pradat
Yoann Pradat
GMGuillaume Montagnac
Guillaume Montagnac
Antibody–drug conjugates have shown impressive clinical outcomes, particularly in metastatic breast cancer, but biomarkers to predict response and resistance remain unidentified. Here we report the results of ICARUS-BREAST01, a phase 2 study evaluating efficacy, safety and biomarkers of response and resistance to patritumab deruxtecan (HER3-DXd), in patients with HR+HER2− metastatic breast cancer, who previously progressed on CDK4/6 inhibitors and one line of chemotherapy. From May 2021 to June 2023, 99 patients were enrolled to receive HER3-DXd 5.6 mg kg−1 intravenously every 3 weeks. The study met its primary endpoint, showing an overall response rate of 53.5% (90% confidence interval [44.8–62.1%]). The most frequent adverse events were fatigue (83%), nausea (75%), diarrhea (53%) and alopecia (40%). Exploratory biomarker analysis of baseline tumor samples suggested preliminary associations between overall response rate and both HER3 spatial distribution and absence of estrogen receptor 1 (ESR1) mutations, as well as between progression-free survival and HER3 expression, pending further validation. Analysis of on-treatment tumor samples showed that treatment efficacy seems to be associated with antibody–drug conjugate intratumoral distribution and interferon response. Overall, HER3-DXd showed promising activity and manageable tolerability in patients with HR+HER2− metastatic breast cancer who progressed on CDK4/6 inhibitors. These findings highlight the need for larger trials to define HER3-DXd efficacy relative to other drugs, including antibody–drug conjugates (ClinicalTrials.gov Identifier: NCT04965766).

1 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
IGI. Garberis
I. Garberis
VGV. Gaury
V. Gaury
CSC. Saillard
C. Saillard
DDD. Drubay
D. Drubay
KEK. Elgui
K. Elgui
MLM. Lacroix-Triki
M. Lacroix-Triki
Accurate risk stratification is critical for guiding treatment decisions in early breast cancer. We present an artificial intelligence (AI)-based tool that analyzes digitized tumor slides to predict 5-year metastasis-free survival (MFS) in patients with estrogen receptor-positive, HER2-negative (ER + /HER2 − ) early breast cancer (EBC). Our deep learning model, RlapsRisk BC, independently predicts MFS and provides significant prognostic value beyond traditional clinico-pathological variables (C-index 0.81 vs 0.76, p < 0.05). Applying a 5% MFS event probability threshold stratifies patients into low- and high-risk groups. After dichotomization, combining RlapsRisk BC with clinico-pathological factors increases cumulative sensitivity (0.69 vs 0.63) and dynamic specificity (0.80 vs 0.76) compared to clinical factors alone. Expert analysis of high-impact regions identified by the model highlights well-established morphological features, supporting its interpretability and biological relevance.